MedTrace Logo

A Study of SPH3127 in the Treatment of Mild to Moderate Ulcerative Colitis

NCT05770609 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 53

Last updated 2025-08-28

No results posted yet for this study

Summary

To preliminarily evaluate the clinical efficacy of the renin inhibitor SPH3127 Tablets in patients with mild to moderate ulcerative colitis with placebo as a control and determine the recommended dose.

Conditions

  • Mild to Moderate Ulcerative Colitis

Interventions

DRUG

SPH3127 Tablets with Dose A

See Arm description

DRUG

SPH3127 Tablets with Dose B

See Arm description

DRUG

SPH3127 Tablets placebo

See Arm description

Sponsors & Collaborators

  • Shanghai Pharmaceuticals Holding Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-19
Primary Completion
2024-09-13
Completion
2024-09-13

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05770609 on ClinicalTrials.gov